Glenmark Builds US OTC Lineup In Wockhardt Deal
Glenmark acquires a portfolio of generic OTCs from Wockhardt marketed in US including famotidine 10- and 20-mgs; cetirizine 5- and 10-mgs; lansoprazole 15-mg delayed-release; and olopatadine hydrochloride 0.1% ophthalmic solution.
You may also be interested in...
Hikma is looking for a new CEO after announcing that chief executive Siggi Olafsson will be leaving the company “to pursue other opportunities” on 24 June. In the meantime, executive chairman and former CEO Said Darwazah will take on his leadership responsibilities.
Hikma is prepared for additional competitors on key products as well as growing price pressure in the US, CEO Siggi Olafsson tells Generics Bulletin in the second part of an exclusive interview.
Glenmark makes buoyant sales projections for Ryaltris, which is set for US debut in the first quarter of FY23 and has also seen launch momentum in several international markets. The rhinitis therapy along with generic Spiriva are seen as pivotal to drive the Indian company's growth in Europe.